November 20, 2019
Registration Now Open For 22nd Annual Meeting in Dallas, TX

The ASIPP 2020 Meeting April 2-4 will be in downtown Dallas at the Hyatt Regency. This will be the 22nd annual meeting for ASIPP and is being held in conjunction with the Texas Pain Society.
Registration is now open. In addition, the Exhibitor Prospectus is available to prospective sponsors and vendors.


Click Here for Exhibitor Prospectus.


 
Reserve Your Hotel Now for ASIPP 2020 Meeting in Dallas

The meeting will be in downtown Dallas at the Hyatt Regency. The room block is now open for reservations. You may book online or by phone. Discounted rates end after March 17.

DISCOUNTED ROOM RATES FOR NIGHTS OF MARCH 31 – APRIL 5
Reserve by Phone
1-877-803-7534
Group Discount Code: G-SIPP

Reserve Online
Click here to reserve your room.

If you have questions about the room block or the meeting, contact Karen Avery at kavery@asipp.org / 270-554-9412 x 4210
Final CMS Payment Rules for Interventional Pain Physicians In-Office, ASC, and HOPD Settings
 
CMS released all 3 payment rules on November 1, 2019.

Here are the links Payment rates for major IPM codes :
 
Physician Fee Schedule:
 
ASC Fee Schedule:
 
HOPD Fee Schedule:
 
The following is important information on the newly released 2020 final payment rules. ASIPP and SIPMS will be sending comment letters to CMS. You may also send comment letters to them on these payment rules no later than 5 p.m. EST on December 2, 2019.
Pain Physician
September/October 2019 Issue Features
 
The September/October issue of Pain Physician features a cost utility analysis of cervical interlaminar epidural injections as well as several systematic reviews, randomized trials and original research.
 
Cost Utility Analysis
Laxmaiah Manchikanti, MD, Vidyasagar Pampati, MSc, Allan Parr, III, MS, Maanasa V. Manchikanti, Mahendra R. Sanapati, MD, Alan D. Kaye, MD, PhD, and Joshua A. Hirsch, MD.

Narrative Review
Inna Blyakhman, MSc, and Krishnan Chakravarthy, MD, PhD.

Comprehensive Review
Ajay B. Antony, MD, Anthony J. Mazzola, MD, Gurpreet S. Dhaliwal, MD, and Corey W. Hunter, MD.

Narrative Review
Gabriel Fregoso, MD, Annie Wang, MD, Kelly Tseng, MD, and Jingping Wang, MD, PhD.

Retrospective Review
Leonardo Kapural, MD, PhD, Nicholas Lee, ., Kevin Neal, MD, and Michael Burchell, MD.
 
JUNE 2020 ABIPP EXAMS
AND COMPETENCY EXAMS
June 27 - June 28, 2020 | Memphis, TN
 
The American Board of Interventional Pain Physicians ( ABIPP ) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management
profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified.
ABIPP now offers the only competency certification program for regenerative medicine.
 
For complete information about the examination requirements and to obtain an application packet, visit www.abipp.org or call 270-554-9412 x4217 or by email at summer@asipp.org.
 
June 27
ABIPP Part I  
Combined CSM/CCPM Exam for ABIPP Path
Competency Exam in Controlled Substance Management
Competency Exam in Coding, Compliance, and
Practice Management
 
June 27-28
ABIPP Part II  
ABIPP Competency Exam
Regenerative Medicine Competency Exam
Endoscopic Lumbar Decompression Competency Exam
 
939 Ridge Lake Blvd. | Memphis, TN 38120  
The Emerging Role of Toxic Adulterants in Street Drugs in the US Illicit Opioid Crisis

Drug overdose deaths in the United States are a substantial public health issue. The number of annual reported drug overdose deaths increased roughly 3-fold, from 23 500 in 2002 to 70 200 in 2017.1,2 Of even greater concern, during this same period, the number of opioid-related overdose deaths increased 4-fold, from 11 900 in 2002 to 47 600 in 2017.2

From 2016 to 2017, rates of opioid-related overdose deaths rose from 42 400 to 47 600, an increase of 12%. Also during this period, death rates associated with cocaine and psychostimulants increased by 34.4% (from 3.2 to 4.3 per 100 000 population) and 33.3% (from 2.4 to 3.2 per 100 000 population), respectively, likely contributing to the rise in overall drug overdose deaths.1 On the other hand, the number of overdose deaths related to either prescription opioids (which include buprenorphine, codeine, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, and tramadol) or heroin did not increase.1


Join the AMA to help us keep our seat in the House of Delegates
 
The American Medical Association (AMA) requires all societies to requalify for membership in the AMA House of Delegates (HOD) every five years. In order for ASIPP to retain our seat, the AMA requires that 20% of ASIPP’s physician members also be members of the AMA. Unfortunately, ASIPP is at risk of losing representation in the AMA because we have fallen below the 20% membership minimum threshold.
 
Membership in the AMA gives us a voice in shaping policy that affects our practice and patients.
We encourage you to join or renew your membership in the AMA. Joining the AMA will further strengthen our specialty’s representation at the national level through the AMA House of Delegates, the AMA’s policymaking body, and strengthen our ability to meet the challenges in health care today with thoughtful, well-organized responses.
 
We strongly encourage you to join the AMA today to help us keep our seat at the table. Right now, you can become a member and pay only half the dues.
 
The stronger our membership, the more we can advance issues that are important to our specialty including improving the Medicare Quality Payment Program, reducing administrative burdens and ensuring accurate coding and reimbursement of our services.
 
Thank you for supporting ASIPP!
 
Click HERE to join today and pay only half price! 


FDA Cracks Down on CBD Products Making Unproven Pain Therapy Claims

The Food and Drug Administration (FDA) has issued a warning letter to Curalef Inc. of Wakefield, Massachusetts for illegally selling unapproved cannabidiol (CBD) products online with unsubstantiated health claims.

The  warning letter  describes how Curaleaf falsely marketed their CBD products on social media websites, online stores and webpages with unproven therapeutic claims. Additionally, some of the products were in violation of the Federal Food, Drug and Cosmetic Act because they were marketed as dietary supplements. The following are a few examples of the claims made by Curaleaf:

  • “CBD was effective in killing human breast cancer cells”
  • “CBD has also been shown to be effective in treating Parkinson’s disease”
  • “CBD has been linked to the effective treatment of Alzheimer’s disease …”
  • “[V]ets will prescribe puppy Xanax to pet owners which can help in certain instances but is not necessarily a desirable medication to give your dog continually. Whereas CBD oil is natural and offers similar results without the use of chemicals”
  • “CBD can also be used in conjunction with opioid medications, and a number of studies have demonstrated that CBD can in fact reduce the severity of opioid-related withdrawal and lessen the buildup of tolerance”
MPR

Harnessing the Power of Placebo
— And what we can do to leverage the effect

Despite continual improvements in medicine, one of the most fascinating aspects of healing remains something we've been aware of for centuries, the placebo effect. Today, I want to talk about what we know currently about the placebo effect and examine what we can do to more effectively leverage it to our advantage. The placebo effect demonstrates the sometimes surprising power of our mindset, thoughts, beliefs, and expectations to produce meaningful changes in the body.

Simply taking a sugar pill under the impression that it's a real medication can not just improve your pain, anxiety, and depression, but also reduce your blood pressure, calm your asthma, and boost your immune system. Placebo surgeries -- yes, you heard me right -- in which the doctor puts patients under anesthesia, cuts them open, and sutures them back up again without doing anything can get people back on their feet again. Placebos don't always take the form of sugar pills or procedures. Their effects aren't always so rosy. Placebo poison ivy can cause real rashes. The mere fear of side effects makes those effects more likely.
 

Study Finds Limited Benefits of Stent Use for Millions With Heart Disease

PHILADELPHIA—Stents and coronary artery bypass surgery are no more effective than intensive drug treatment and better health habits in preventing millions of Americans from heart attacks and death, a large study found, shedding new light on a major controversy in cardiology.

Researchers and doctors have fiercely debated for years how best to treat people who have narrowed coronary arteries but aren’t suffering acute symptoms.

The standard treatment has been to implant stents—wire mesh tubes that open up clogged arteries—or to perform bypass surgery, redirecting blood around a blockage. Those procedures are performed even though these patients either have no symptoms or feel chest pain only when they climb a few flights of stairs or exert themselves in some other way.


Access to this article may be limited
Verma Slams Nonprofit Hospitals That Sue Patients for Payment
 
WASHINGTON -- Centers for Medicare & Medicaid Services Administrator Seema Verma blasted nonprofit hospitals for suing patients, plugged new price transparency rules, and blamed the uptick in the nation's uninsured rate on the Affordable Care Act (ACA), during an interview and panel discussion at the U.S. News & World Report Healthcare of Tomorrow summit Tuesday.

"We're hearing more and more stories about hospitals that are going after patients that don't have health insurance and ... they're [nonprofit] hospitals. They're taking people to court over prices that they would never charge anybody else," Verma said during a Q&A with Brian Kelly, U.S. News editorial director and executive vice president.



Interventional Pain Management Reports is an Open Access online journal, a peer-reviews journal dedicated to the publication of case reports, brief commentaries and reviews and letters to the editor. It is a peer-reviewed journal written by and directed to an audience of interventional pain physicians, clinicians and basic scientists with an interest in interventional pain management and pain medicine. 

Interventional Pain Management Reports is an official publication of the American Society of Interventional Pain Physicians (ASIPP) and is a sister publication of Pain Physician . Interventional Pain Management Reports Interventional Pain Management Reports is an open access journal, available online with free full manuscripts.  

The benefits of publishing in an open access journal that has a corresponding
print edition journal are:  
  • Your article will have the potential to obtain more citations.
  • Your article will be peer-reviewed and published faster than other journals.
  • Your article can be read by a potentially much larger audience compared with traditional subscription-only journals.  
  • Open Access journals are FREE to view, download and to print.

So submit today your:
  • Case Reports
  • Technical Reports
  • Editorials
  • Short Perspectives

2019 MIPS Reporting? Start Now.
MIPS-eligible clinicians must report a full year of data. Don’t fall behind – keep up with NIPM-QCDR.
 
MIPS 2019 has brought larger payment adjustments and greater reporting requirements, including a 365-day performance period for the Quality and Cost categories. The sooner you start your MIPS reporting for 2019, the better.
Sign up today to use ASIPP’s NIPM-QCDR for MIPS.
This powerful tool makes MIPS reporting easy through the use of our new patient-reported outcomes measures for 2019, which ease the burden on providers and reduces costly EMR integration.

Get started today at ASIPP.ArborMetrix.net

State Society News 


Send in your state society meeting news to Holly Long, hlong@asipp.org
ASIPP | Pain Physician Journal | Phone | Fax | Email